Vixtimotamab
Based on 1 Customer Validation
Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML).
For research use only. We do not sell to patients.
- Purity: 97.29%
- CAS No.: 2243775-32-6
- Molecular Weight:103.14 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
[V-kappa-VH-V-lambda-VH']-noncovalent dimer (tandem diabody)
Human
CD3E & CD33
Vixtimotamab (TandAb T564; 24 h) induces CD25 and CD69 with EC50s of 1 pM and 2 pM, respectively[1].
Vixtimotamab (TandAb T564; 4 days) induces T-cell proliferation in PBMCs with an EC50 of 3 pM[1].
Vixtimotamab (TandAb T564; 25 pM, 48 h) shows cytotoxicity against HL-60 and KG-1a cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HL-60 and KG-1a cells
-
Concentration:25 pM
-
Incubation Time:48 h
-
Result:Showed cytotoxicity of 86.0±1.4% and 81.3±1.5% against HL-60 and KG-1a cells, respectively.
Vixtimotamab (TandAb T564; 50 μg/mouse/d, i.v.; 7 days) substantially inhibits tumor growth in an established HL-60 xenograft NOD/scid mouse model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:8-week-old NOD/scid female mice, weighing 20.7 ± 1.48 g, prophylactic HL-60 graft model[1]
-
Dosage:0.1, 1, or 10 μg/mouse
-
Administration:Intravenous injection, on days 0, 1, 2, 3, and 4
-
Result:Demonstrated dose-dependent tumor growth delay.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
[V-kappa-VH-V-lambda-VH']-noncovalent dimer (tandem diabody)
ELISA, FACS, Functional assay
-
Immobilized Vixtimotamab can bind Human CD3 epsilon/CD3e Protein (ECD, His Tag). The EC50 for this effect is 4.95 ng/mL. -
Immobilized Vixtimotamab can bind Human Siglec-3/CD33 Protein (ECD, His Tag). The EC50 for this effect is 4.95 ng/mL. -
Flow cytometric analysis of 1×106 Jurkat cells labelling CD3E (red) with Vixtimotamab (HY-P99958). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black). -
Flow cytometric analysis of 1X106 THP-1 cells labeling CD33 with Vixtimotamab (HY-P99958, red). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF488-conjugated Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 2243775-32-6
-
Appearance Liquid
-
Molecular Weight 103.14 kDa
-
Color Colorless to light yellow
-
SMILES
[Vixtimotamab]
-
Synonyms
AMV-564; TandAb T564
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)